Interaction between linezolid and Mycobacterium tuberculosis in an experimental in vitro model

APMIS

Volumn 119, Issue 4-5, 2011, Pages 304-308

  Cremades, Rosa ^a   Rodríguez, Juan Carlos ^a   Garcia Pachón, Eduardo ^a   Galiana, Antonio ^a   Ruiz García, Montserrat ^a   López, Pilar ^a   Royo, Gloria ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Bactericidal activity; Linezolid; Multi resistant tuberculosis; Mutants; Mycobacterium tuberculosis

Indexed keywords

LINEZOLID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; EXPERIMENTAL DESIGN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79954710568     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02735.x     Document Type: Article

References (22)

1. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.
2. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134:187-92.
3. Rodríguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20:464-7.
4. Rodríguez JC, Cebrián L, López M, Ruiz M, Jiménez I, Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004;53:441-4.
5. Rodríguez JC, Escribano I, Gómez RA, García-Pachón E, Navarro A, Royo G. Present and future treatment of mycobacteria. Anti-Infective Agents Medicinal Chemistry 2008;7:1-11.
6. Hillemann D, Rüsch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008;52:800-1.
7. Gordillo S, Guirado E, Gil O, Diaz J, Amat I, Molinos S, et al. Usefulness of acr expression for monitoring latent Mycobacterium tuberculosis bacilli in 'in vitro' and 'in vivo' experimental models. Scand J Immunol 2006;64:30-9.
8. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2296-9.
9. Fortún J, Martín-Dávila P, Navas E, Perez-Elías MJ, Cobo J, Tato M, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-5.
10. Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 2006;42:525-32.
11. Markantonis SL, Vlachos K, Anagnostaki M, Boutzouka E, Panidis D, Baltopoulos G. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006;50:3971-6.
12. Yew WW, Chang KC, Chau CH. What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?. Eur Respir J 2009;34:1492-4.
13. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998;2:187-99.
14. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009;10:381-401.
15. Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy?. J Antimicrob Chemother 2001;47:117-8.
16. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-5.
17. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2600-6.
18. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
19. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004;9:1059-72.
20. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8.
21. Gumbo T. New susceptibility breakpoints for first line antituberculosis drugs, based on antimicrobial PK/PD science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010;54:1484-91.
22. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2009;53:3981-4.